Q32 Bio Inc. (QTTB) P/E Ratio History
ExpensiveTrading at 5.2x vs 5Y avg 1.9x · 100th percentile · Material premium to history · Data 2025–2026
Loading P/E history...
P/E Ratio Analysis
As of June 12, 2026, Q32 Bio Inc. (QTTB) trades at a price-to-earnings ratio of 5.2x, with a stock price of $12.70 and trailing twelve-month earnings per share of $2.36.
The current P/E is 172% above its 5-year average of 1.9x. Over the past five years, QTTB's P/E has ranged from a low of 1.4x to a high of 2.4x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.1x, QTTB trades at a 77% discount to its sector peers. The sector includes 235 companies with P/E ratios ranging from 0.0x to 187.5x.
Relative to the broader market, QTTB trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our QTTB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
QTTB Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
QTTB P/E vs Peers
Immunology and Inflammation Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $39B | 124.2 | - | +207%Best | |
| $64B | 14.7Lowest | 2.33Best | +8% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
QTTB Historical P/E Data (2025–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $6.42 | $2.66 | 2.4x | +25% |
| FY2025 Q4 | Dec 31 2025 | $3.32 | $2.30 | 1.4x | -25% |
Average P/E for displayed period: 1.9x
What if you invested $1,000 in QTTB back in 2025?
Total return with dividends reinvested · 1+ years of data
Calculate ReturnsHow much would $100/month in QTTB be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs QTTB Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationQTTB vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowQTTB — Frequently Asked Questions
Quick answers to the most common questions about buying QTTB stock.
What is QTTB's P/E ratio?
Q32 Bio Inc. (QTTB) trailing twelve-month P/E ratio is 5.2x, based on TTM diluted EPS of $2.36. The 5-year average P/E is 1.9x and the historical range spans 1.4x to 2.4x.
Is QTTB stock overvalued or undervalued?
QTTB trades at 5.2x P/E, above its 5-year average of 1.9x. The 100th percentile ranking within the 1.4x–2.4x historical range indicates a premium to historical valuation.
Is QTTB stock expensive?
Yes, QTTB is expensive relative to its own history. The current P/E of 5.2x is above the 5-year average of 1.9x. The stock sits at the 100th percentile of its 5-year valuation range.
What is QTTB's historical P/E range?
Over the past 5 years, QTTB's P/E ratio has ranged from 1.4x to 2.4x, with a median of 2.4x and an average of 1.9x. The current P/E of 5.2x places the stock at the 100th percentile of this range. Full historical data spans 2025–2026.
How does QTTB's P/E compare to the S&P 500?
QTTB trades at 5.2x P/E versus the S&P 500 median of 24.9x. The 79% discount to the market suggests lower growth expectations or perceived higher risk.
How does QTTB's valuation compare to Healthcare peers?
Q32 Bio Inc. P/E of 5.2x compares to the Healthcare sector median of 23.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is QTTB's PEG ratio?
QTTB PEG ratio is N/A, based on a P/E of 5.2x and EPS growth of 136.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is QTTB's earnings yield?
QTTB earnings yield is 19.06%, the inverse of its 5.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.